R. Kyle, MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND SOLITARY PLASMACYTOMA, Hematology/Oncology Clinics of North America, vol.11, issue.1, pp.71-87, 1997.
DOI : 10.1016/S0889-8588(05)70416-0

R. Casini, Les gammapathies monoclonales en médecine ambulatoire : étude prospective de 300 électrophoreses des protéines demandées de facon systématique par des omnipraticiens des alpes-maritimes chez des patients de plus de 60 ans, Thèse Nice, 1992.

R. Kyle, B. Durie, and D. Rajkumar, Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma. IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management Leukemia, pp.1121-1127, 2010.

J. Waldenström, Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia -a new syndrome ? Acts Med Scand, pp.216-247, 1944.

R. Kyle, Monoclonal gammopathy of undetermined significance, The American Journal of Medicine, vol.64, issue.5, pp.814-840, 1978.
DOI : 10.1016/0002-9343(78)90522-3

URL : https://hal.archives-ouvertes.fr/hal-00945713

. Microbiologybook and . Org, Microbiologie et immunologie On line, 2016.

P. Touzeau and P. Moreau, Gammapathies monoclonales de signification indéterminée. EMC - Hématologie, 2012.

R. Kyle, T. Therneau, and S. Rajkamar, Prevalence of Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine, vol.354, issue.13, pp.1362-1369, 2006.
DOI : 10.1056/NEJMoa054494

R. Kyle, T. Therneau, and S. Rajkumar, A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine, vol.346, issue.8, pp.564-569, 2002.
DOI : 10.1056/NEJMoa01133202

I. Myeloma and W. Group, Criteria for the clasification of monoclonal gammopathies, multiple myeloma and related disorders, Br J haematol, vol.121, issue.121, pp.749-57, 2003.

S. Rajkumar, R. Kyle, and F. Buadi, Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence, Mayo Clinic Proceedings, vol.85, issue.10, pp.945-948, 2010.
DOI : 10.4065/mcp.2010.0520

L. Melton, S. Rajkumar, and S. Khosla, Fracture Risk in Monoclonal Gammopathy of Undetermined Significance, Journal of Bone and Mineral Research, vol.11, issue.Suppl 2, pp.25-30, 2004.
DOI : 10.1359/jbmr.0301212

S. Kristinsson, R. Pfeiffer, and M. Bjorkholm, Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study, Blood, vol.115, issue.24, pp.4991-4998, 2010.
DOI : 10.1182/blood-2009-11-252072

J. Kelly, R. Kyle, O. Brien, P. Dyck, and P. , Prevalence of monoclonal protein in peripheral neuropathy, Neurology, vol.31, issue.11, pp.1480-1483, 1991.
DOI : 10.1212/WNL.31.11.1480

R. Kyle, E. Remstein, and T. Therneau, Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma, New England Journal of Medicine, vol.356, issue.25, pp.2582-90, 2007.
DOI : 10.1056/NEJMoa070389

S. Rajkumar, M. Dimopoulos, A. Palumbo, and J. Blade, International Myéloma Working group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, pp.538-586, 2014.

N. Leug, F. Bridoux, and C. Hutchison, Monoclonal gammopathy of renal significance (MGRS) : when MGUS is no longer undertermined or insignificant, Blood. 2012, vol.120, issue.22, pp.4292-4297

R. Guièze, A. Moreau, and S. Dupire, Leucémie à plasmocytes, Hématologie, vol.11, issue.3, pp.217-225, 2005.

O. Mathieu, C. De-bazelaire, and Y. Uzunhan, Myélome et plasmocytome : aspects radiologiques des localisations extra-osseuses. . SFRNET. [Online] [Cited: Juillet 28, pp.5-8, 2005.

. Haute-autorité-de-santé, Dosage sérique des chaînes légères, pp.6-7, 2006.

A. Labruyere and H. Partouche, Elaboration et validation d'un référentiel de prescription et de décision en cas de pic monoclonal. Exercer, pp.68-74, 2011.

. Haute-autorité-de-santé, Tumeur maligne, affection maligne du tissu, lymphatique ou hématopoïétique : Myélome Multiple. [Online] Décembre 2010. [Cited: 06 2016, 01

J. Katzmann, Screening panels for monoclonal gammopathies : time to change, Clin Biochem Rev, vol.30, pp.105-111, 2009.

J. Katzmann, R. Kyle, and J. Benson, Screening Panels for Detection of Monoclonal Gammopathies, Clinical Chemistry, vol.55, issue.8, pp.1714-1720, 2009.
DOI : 10.1373/clinchem.2009.126664

R. Kyle, B. Durie, and S. Rajkumar, Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management, Leukemia, vol.102, issue.6, pp.1121-1127, 2010.
DOI : 10.1182/blood-2007-08-108357

J. Blade, A. Lopez-guillermo, and C. Rozman, Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance, British Journal of Haematology, vol.64, issue.3, pp.391-394, 1992.
DOI : 10.2307/2529177

O. Lefebvre, Prise en charge d'une découverte d'une gammpathie monoclonale en ville par le médecin généraliste, Thèse Paris VI, 2013.

. Biominis, Chaînes légères libres d'immunoglobulines. [Online] [Cited: 07 07, 2016.

R. Kyle, Monoclonal gammopathy of undertermined significance (MGUS) and Smoldering (asymptomatic) multiple myeloma : IMWG consensus perspective risk factors for progression and guidelines for monitoring and management. leukemia, pp.1121-1128, 2010.